Decreased expression of indoleamine 2, 3-dioxygenase in villous stromal endothelial cells of placentas with preeclampsia and/or fetal growth restriction

Placenta ◽  
2016 ◽  
Vol 45 ◽  
pp. 121
Author(s):  
Naoyuki Iwahashi ◽  
Madoka Yamamoto ◽  
Tamaki Yahata ◽  
Mika Mizoguchi ◽  
Sakiko Nanjo ◽  
...  
2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Fieke Terstappen ◽  
Jorg J. A. Calis ◽  
Nina D. Paauw ◽  
Jaap A. Joles ◽  
Bas B. van Rijn ◽  
...  

Abstract Background Fetal growth restriction (FGR) is associated with an increased susceptibility for various noncommunicable diseases in adulthood, including cardiovascular and renal disease. During FGR, reduced uteroplacental blood flow, oxygen and nutrient supply to the fetus are hypothesized to detrimentally influence cardiovascular and renal programming. This study examined whether developmental programming profiles, especially related to the cardiovascular and renal system, differ in human umbilical vein endothelial cells (HUVECs) collected from pregnancies complicated by placental insufficiency-induced FGR compared to normal growth pregnancies. Our approach, involving transcriptomic profiling by RNA-sequencing and gene set enrichment analysis focused on cardiovascular and renal gene sets and targeted DNA methylation assays, contributes to the identification of targets underlying long-term cardiovascular and renal diseases. Results Gene set enrichment analysis showed several downregulated gene sets, most of them involved in immune or inflammatory pathways or cell cycle pathways. seven of the 22 significantly upregulated gene sets related to kidney development and four gene sets involved with cardiovascular health and function were downregulated in FGR (n = 11) versus control (n = 8). Transcriptomic profiling by RNA-sequencing revealed downregulated expression of LGALS1, FPR3 and NRM and upregulation of lincRNA RP5-855F14.1 in FGR compared to controls. DNA methylation was similar for LGALS1 between study groups, but relative hypomethylation of FPR3 and hypermethylation of NRM were present in FGR, especially in male offspring. Absolute differences in methylation were, however, small. Conclusion This study showed upregulation of gene sets related to renal development in HUVECs collected from pregnancies complicated by FGR compared to control donors. The differentially expressed gene sets related to cardiovascular function and health might be in line with the downregulated expression of NRM and upregulated expression of lincRNA RP5-855F14.1 in FGR samples; NRM is involved in cardiac remodeling, and lincRNAs are correlated with cardiovascular diseases. Future studies should elucidate whether the downregulated LGALS1 and FPR3 expressions in FGR are angiogenesis-modulating regulators leading to placental insufficiency-induced FGR or whether the expression of these genes can be used as a biomarker for increased cardiovascular risk. Altered DNA methylation might partly underlie FPR3 and NRM differential gene expression differences in a sex-dependent manner.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3946-3946
Author(s):  
Agostino Cortelezzi ◽  
Nicola Stefano Fracchiolla ◽  
Michela Cortiana ◽  
Maria Cristina Pasquini ◽  
Ilaria Silvestris ◽  
...  

Abstract Pre-eclampsia (PE) is a pregnancy-associated disorder of unknown cause. The pathological changes associated with PE (edema, proteinuria, coagulopathy, and renal and hepatic abnormalities) suggest a systemic maternal vascular dysfunction. PE is also associated with placental development defects and fetal growth restriction. The generation of vessels is divided into angiogenesis (the sprouting of capillaries from pre-existing vessels) and vasculogenesis, the development of blood vessels from in situ differentiating endothelial cells (ECs), which has been considered as occurring only in the prenatal period. However, circulating endothelial precursors (CEPs) are also present in the peripheral blood (PB) of adults and, in the case of pregnant women, may play important roles in vascularising the uterine endometrium at the time of embryo implantation and placentation. Furthermore, it has been found that the number of mature circulating endothelial cells (CECs) is increased in the PB of patients affected by cancer, sickle cell anemia, myocardial infarction or infections, but they have not been extensively studied in PE patients. Inorder to test the hypothesis that CEPs may be involved in the pathogenesis of PE and that CECs may represent a marker of the severity of ongoing vascular damage, we used flow cytometry to quantify the number of CEPs and CECs in 17 PE patients and 13 healthy pregnant women of similar gestational age. Immunocytofluorimetric assays showed that resting CECs were negative for CD45 but positive for P1H12 and CD31, whereas CEPs were positive for CD133 and CD34. Our 13 healthy controls had a mean number of 20.8 CECs/ml (range 9.22–77.11) and 1.05 CEPs/ml (range 0.07–3.43); the corresponding numbers in 27 samples from the 17 PE cases were 25.46/ml (range 1.65–126.34) and 0.42/ml (range 0–15.45). The PE cases had significantly fewer CEPs than the controls (p <0.05, Mann-Whitney test). Among the PE cases, we compared the samples collected during severe (16 samples) and mild PE (11 samples): the severe PE group showed significantly more CECs than the mild PE group (29.03/ml [range 1.65–120.78] vs 13.58/ml [range 7.67–126.34; p <0.02, Mann-Whitney test) but not CEPs (0.51/ml [range 0–15.45] vs 0.23/ml [range 0–1.41]). In conclusion, there is a reduction in CEPs during PE that may be consistent with an impaired response to vascular damage. As CEPs seem to play a crucial role in the vasculogenesis of the placental bed during pregnancy, this finding is consistent with the fetal growth restriction and placental maturation defects observed during pregnancy. Furthermore, the women with severe PE had more CECs (a marker of ongoing endothelial damage) than those with mild PE. Our findings are consistent with the hypothesis that PE is characterised by a systemic maternal vascular dysfunction, with reduced repair potential (fewer CEPs), and the increased number of CECs in the peripheral blood of women with severe PE correlates with disease severity. Further longitudinal studies are needed to verify their prognostic role.


Author(s):  
Yakubova D.I.

Objective of the study: Comprehensive assessment of risk factors, the implementation of which leads to FGR with early and late manifestation. To evaluate the results of the first prenatal screening: PAPP-A, B-hCG, made at 11-13 weeks. Materials and Methods: A retrospective study included 110 pregnant women. There were 48 pregnant women with early manifestation of fetal growth restriction, 62 pregnant women with late manifestation among them. Results of the study: The risk factors for the formation of the FGR are established. Statistically significant differences in the indicators between groups were not established in the analyses of structures of extragenital pathology. According to I prenatal screening, there were no statistical differences in levels (PAPP-A, b-hCG) in the early and late form of FGR.


2018 ◽  
pp. 184-195
Author(s):  
Minh Son Pham ◽  
Vu Quoc Huy Nguyen ◽  
Dinh Vinh Tran

Small for gestational age (SGA) and fetal growth restriction (FGR) is difficult to define exactly. In this pregnancy condition, the fetus does not reach its biological growth potential as a consequence of impaired placental function, which may be because of a variety of factors. Fetuses with FGR are at risk for perinatal morbidity and mortality, and poor long-term health outcomes, such as impaired neurological and cognitive development, and cardiovascular and endocrine diseases in adulthood. At present no gold standard for the diagnosis of SGA/FGR exists. The first aim of this review is to: summarize areas of consensus and controversy between recently published national guidelines on small for gestational age or fetal growth restriction; highlight any recent evidence that should be incorporated into existing guidelines. Another aim to summary a number of interventions which are being developed or coming through to clinical trial in an attempt to improve fetal growth in placental insufficiency. Key words: fetal growth restriction (FGR), Small for gestational age (SGA)


Author(s):  
I.V. Komarova, A.A. Nikiforenko, A.V. Fedunyak

Literature reports of placental mosaicism, including trisomy 22, were analyzed. The chance of correlation of placental aneuploidy with fetus aneuploidy, also the probability of complications in pregnancy and fetal growth restriction and postnatal patients growth in the cases of confined placental mosaicism, were demonstrated. The case of prenatal diagnosis of confined placental mosaicism of trisomy 22 with favorable outcome is presented. The necessity of cytogenic assay of amniocytes and fetal lymphocytes in the case of placental heteroploidy diagnosis was emphasized.


Sign in / Sign up

Export Citation Format

Share Document